| 1 |
How might using gold nanoparticles in electrochemical sensors enhance early-stage disease detection?
|
2. By increasing surface interactions for more accurate biomarker capture |
|
Gold nanoparticles (GNPs) have a high surface-to-volume ratio, which provides a significantly larger surface area for interactions with biomolecules such as glucose, DNA, proteins, or antigens. This allows more target molecules to bind effectively to the sensor surface, resulting in more accurate and sensitive detection.
Moreover, GNPs have excellent electrical conductivity, which enhances the electrochemical signal generated when biomarkers bind to the sensor. This signal amplification enables the detection of diseases at very early stages, even when the concentration of biomarkers is extremely low (ultra-low concentrations). |
Nanotechnology Principle: Nanomaterials offer more surface area for molecular interactions, improving sensor sensitivity. (Pradeep, T. Nano: The Essentials, 2007)
Electrochemical Biosensing Principle: Gold nanoparticles act as electrochemical transducers, enhancing signal output and improving detection limits in biosensors.
Key references:
Wang, J. (2005). Nanomaterial-based electrochemical biosensors. Analytical and Bioanalytical Chemistry, 384(3), 546–552.
Dykman, L. A., & Khlebtsov, N. G. (2012). Gold nanoparticles in biomedical applications: recent advances and perspectives. Chemical Society Reviews, 41(6), 2256–2282. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following best explains how label-free electrochemical sensors support point-of-care medical diagnostics?
|
3. They provide direct measurement of target molecules with minimal preparation |
|
Label free electrochemical sensors are designed to directly detect target molecules (e.g., proteins, DNA, glucose) without the need for labeling agents, such as fluorescent dyes or radioactive markers. This direct detection makes the process simpler, faster, and more cost effective, especially in point of care (POC) settings, where rapid results and minimal sample processing are essential.
These sensors often use changes in electrical properties (e.g., impedance, current, or potential) when a target molecule binds to a recognition surface (like an antibody or aptamer). Because there's no labeling step, the procedure involves fewer reagents, less equipment, and can be miniaturized and automated making it ideal for bedside or home diagnostics. |
Label free detection principle: Based on direct physical or chemical interaction of analytes with a sensor surface, measured through changes in electrical signals no chemical modification or labeling needed.
Electrochemical biosensor theory: Signal generation comes from molecular binding events causing changes in impedance, capacitance, or current, detectable by an electrode interface.
Advantages for POC use:
Rapid turnaround time
Reduced cost and complexity
Suitable for miniaturized devices
Key references :
Paleček, E., & Fojta, M. (2007). Electrochemical biosensors for DNA hybridization and DNA damage. Biosensors and Bioelectronics, 22(9), 1861–1875.
Lisdat, F., & Schäfer, D. (2008). The use of electrochemical impedance spectroscopy for biosensing. Analytical and Bioanalytical Chemistry, 391(5), 1555–1567.
Wang, J. (2006). Electrochemical biosensors: Towards point-of-care cancer diagnostics. Biosensors and Bioelectronics, 21(10), 1887–1892. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
Why is electrochemical transduction considered advantageous over optical transduction in medical diagnostic sensors?
|
2. It is more compatible with smartphone integration for remote analysis |
|
Electrochemical transduction is considered advantageous in medical diagnostic sensors because it allows miniaturization, low power consumption, and easy data digitization, making it highly compatible with portable devices and smartphones. This enables remote health monitoring, telemedicine, and point-of-care (POC) diagnostics, especially in resource limited settings.
Unlike optical transduction, which often requires bulky and expensive equipment (e.g., lasers, lenses, spectrometers), electrochemical sensors only need small electrodes and low voltage electronics. This makes them easier to embed in wearable devices or smartphone-connected readers, offering real-time analysis and cloud based data sharing. |
Electrochemical sensing principle: Converts biological recognition events (e.g., antibody-antigen binding) into electrical signals such as current, voltage, or impedance. These can be easily processed, transmitted, and stored by small electronic systems, including mobile apps.
Advantage over optical methods: Optical systems require careful light path alignment, high sensitivity to environmental interference, and are more expensive to miniaturize. Electrochemical sensors are less affected by light, easier to mass-produce, and consume less power.
Integration with mobile tech:
Widely studied and used in smartphone based diagnostics
Supports decentralized healthcare and wearable biosensors
Key references:
Vashist, S. K., et al. (2015). Technologies for next-generation point-of-care testing. TrAC Trends in Analytical Chemistry, 66, 19–31.
Zhang, Y., et al. (2021). Smartphone-based electrochemical biosensors: A critical review. Biosensors and Bioelectronics, 192, 113493.
Wang, J. (2008). Electrochemical biosensors: Towards point-of-care cancer diagnostics. Biosensors and Bioelectronics, 21(10), 1887–1892. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which action would most effectively increase specificity in a sensor designed to detect a single disease biomarker?
|
3. Functionalizing the electrode with disease-specific aptamers |
|
To increase specificity in a biosensor designed to detect a single disease biomarker, the most effective method is to functionalize the electrode surface with aptamers that are highly specific to that biomarker. Aptamers are short, single-stranded DNA or RNA molecules that can bind with high affinity and specificity to a target molecule, similar to antibodies.
By attaching aptamers that are tailored to recognize only the target biomarker, the sensor can selectively bind that molecule even in complex biological fluids like blood or saliva. This dramatically reduces false positives and cross-reactivity, enhancing both accuracy and reliability of diagnosis. |
Specificity principle in biosensors : Specificity depends on the recognition element used (e.g., aptamer, antibody, enzyme). Functionalizing a sensor with target-specific molecules ensures selective detection. Aptamers are chemically stable and can be synthesized with high precision for specific disease markers.
Advantages of aptamers:
High binding affinity (low dissociation constants)
Customizable via SELEX (Systematic Evolution of Ligands by Exponential Enrichment)
Chemically modifiable for stable immobilization on sensor surfaces
Key references:
Song, S., et al. (2008). Aptamer-based biosensors. Trends in Analytical Chemistry, 27(2), 108–117.
Labib, M., & Sargent, E. H. (2016). Aptamer-based electrochemical biosensors for clinical diagnostics: recent advances and challenges. Chemical Reviews, 116(16), 9001–9090.
Wu, Y., et al. (2021). Aptamer-based biosensors for detection of disease biomarkers in point-of-care diagnostics. Biosensors and Bioelectronics, 171, 112748. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
In a scenario where a sensor must detect ultra-low concentrations of a cancer biomarker, which modification is most critical?
|
3. Incorporating nanostructures to increase surface-to-volume ratio |
|
When detecting ultra low concentrations of a cancer biomarker, the sensor’s sensitivity is crucial. Incorporating nanostructures such as gold nanoparticles, carbon nanotubes, or nanowires significantly increases the surface-to-volume ratio of the sensor. This modification allows more biomolecules to interact with the sensor surface, enhancing binding efficiency and leading to stronger and more detectable signals, even at very low analyte concentrations.
Nanostructures also often have excellent electrical conductivity, which improves signal amplification, making the sensor more responsive to even tiny changes caused by target molecule binding. This is essential for early-stage cancer detection, where biomarkers are present in minute quantities. |
Surface-to-volume ratio theory:
As structures decrease in size (e.g., into the nanometer scale), their surface area becomes proportionally larger compared to volume. A higher surface area increases the number of available binding sites for target molecules, which enhances sensitivity.
Role of nanomaterials in biosensing:
Improve signal-to-noise ratio
Enable ultrasensitive detection
Allow for miniaturization of sensor systems
Key references:
Wang, J. (2005). Nanomaterial-based electrochemical biosensors. Analytical and Bioanalytical Chemistry, 384(3), 546–552.
Dykman, L. & Khlebtsov, N. (2012). Gold nanoparticles in biomedical applications. Chemical Society Reviews, 41(6), 2256–2282.
Yang, Y., et al. (2017). Nanomaterial-enabled sensors for the detection of circulating tumor cells and biomarkers. Biosensors and Bioelectronics, 91, 804–816. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
Why might two electrochemical sensors using the same nanomaterial produce inconsistent results?
|
3. Variations in nanomaterial synthesis affect structural uniformity |
|
Even when using the same type of nanomaterial, such as gold nanoparticles or carbon nanotubes, inconsistencies in the synthesis process (e.g., temperature, pH, precursor concentration, or reaction time) can result in variations in particle size, shape, surface charge, and distribution. These structural differences can significantly affect the electrochemical properties of the material, including conductivity, surface area, and binding efficiency with bioreceptors.
This leads to inconsistent sensor performance, such as variability in signal strength, sensitivity, and detection limits—even when the same nanomaterial is intended to be used. Achieving high reproducibility in nanomaterial-based sensors requires precise control over synthesis and fabrication protocols. |
Nanomaterial sensitivity to synthesis conditions:
Nanomaterials exhibit properties that are highly dependent on their physical and chemical structure. For example, a slight variation in nanoparticle diameter can cause a significant difference in surface-to-volume ratio and electron transfer rate—both critical to sensor function.
Reproducibility issue in nanotechnology:
One of the known challenges in nanosensor development is achieving batch-to-batch consistency due to the complex interplay of chemical and physical factors during synthesis.
Key references:
Dreaden, E. C., et al. (2012). The golden age: gold nanoparticles for biomedicine. Chemical Society Reviews, 41(7), 2740–2779.
Li, X., & Vallet-Regí, M. (2020). Reproducibility and uniformity in nanomaterial-based sensors. Sensors, 20(14), 3963.
Ghosh, S. K., & Pal, T. (2007). Interparticle coupling effect on the surface plasmon resonance of gold nanoparticles: from theory to applications. Chemical Reviews, 107(11), 4797–4862. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
Which characteristic makes nanotechnology-based electrochemical sensors especially suitable for wearable medical devices?
|
3. They allow miniaturization without losing sensitivity |
|
Nanotechnology-based electrochemical sensors are ideal for wearable medical devices because they can be miniaturized to fit into compact, flexible, or even stretchable formats without compromising performance. Thanks to their high surface-to-volume ratio, excellent conductivity, and biocompatibility, nanomaterials (like gold nanoparticles, carbon nanotubes, graphene) enable sensors to detect very low concentrations of biomarkers in sweat, saliva, or interstitial fluid—while being small, lightweight, and energy-efficient.
This makes them highly suited for continuous health monitoring, such as for glucose levels, heart rate, or hydration status, in real-time on the human body. |
Miniaturization with maintained sensitivity:
Nanosensors offer high signal-to-noise ratios and strong molecular interaction capabilities even at very small scales, making them perfect for wearable formats.
Properties of nanomaterials:
High electrical conductivity
Mechanical flexibility (especially materials like graphene)
Surface functionalization potential for selective detection
Integration into wearables:
These sensors can be embedded into textiles, skin patches, wristbands, or even microneedles due to their scalability and low power requirements.
Key references:
Gao, W., et al. (2016). Fully integrated wearable sensor arrays for multiplexed in situ perspiration analysis. Nature, 529(7587), 509–514.
Ray, T. R., et al. (2019). Bio-integrated wearable systems: A comprehensive review. Chemical Reviews, 119(8), 5461–5533.
Bandodkar, A. J., & Wang, J. (2014). Non-invasive wearable electrochemical sensors: a review. Trends in Biotechnology, 32(7), 363–371. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What would likely happen if the bioreceptor layer is poorly immobilized on the sensor surface?
|
3. Target biomolecules may not bind effectively, leading to weak or inaccurate signals |
|
If the bioreceptor layer (such as antibodies, aptamers, or enzymes) is poorly immobilized on the sensor surface, it can detach, denature, or become misoriented, which severely reduces its ability to capture target biomolecules. This compromises the specificity and sensitivity of the biosensor.
As a result, the binding efficiency between the bioreceptor and the analyte (e.g., cancer biomarkers, glucose, etc.) is reduced, causing weak signal output or false negatives, and thus inaccurate detection. Proper immobilization ensures that the bioreceptors are stably attached, correctly oriented, and remain active throughout the sensing process. |
Biosensor principle:
A biosensor relies on the specific interaction between a bioreceptor and a target molecule. For this to work efficiently, the bioreceptor must be securely and functionally immobilized on the sensor surface.
Immobilization methods matter:
Techniques like covalent bonding, physical adsorption, and cross-linking affect bioreceptor stability, orientation, and activity.
Impact of poor immobilization:
Reduced active binding sites
Loss of reproducibility and sensor lifetime
Increased signal variability
Key references:
Sassolas, A., et al. (2012). Immobilization strategies for aptamer-based biosensors. Sensors, 12(1), 934–960.
Thévenot, D. R., et al. (2001). Electrochemical biosensors: recommended definitions and classification. Biosensors and Bioelectronics, 16(1–2), 121–131.
Turner, A. P. F. (2013). Biosensors: sense and sensibility. Chemical Society Reviews, 42(8), 3184–3196. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
Which modification would most directly enhance electron transfer in the sensor system?
|
2. Incorporating carbon nanotubes on the electrode surface |
|
Carbon nanotubes (CNTs) are highly conductive nanomaterials with exceptional electron mobility, making them ideal for enhancing electron transfer at the electrode–electrolyte interface in electrochemical sensors. When CNTs are incorporated onto the electrode surface, they significantly improve electrical conductivity, increase electroactive surface area, and provide efficient electron pathways between the bioreceptor layer and the transducer.
This leads to faster and stronger electrochemical signals, enhancing sensor performance—especially in detecting low-abundance analytes. In contrast, insulating materials or smoother (less rough) electrodes reduce active surface area and hinder signal transmission. |
Electron transfer in electrochemical sensors:
Efficient electron transfer between the sensing surface and the electrode is critical for strong and rapid signal output. CNTs offer π-conjugated structures and high aspect ratios, which facilitate direct electron transfer (DET).
Advantages of carbon nanotubes:
High electrical conductivity (~10⁶–10⁷ S/m)
Chemical stability
Ability to act as both a scaffold and a conductive bridge between bioreceptors and electrodes
Key references:
Wang, J. (2005). Carbon-nanotube based electrochemical biosensors: A review. Electroanalysis, 17(1), 7–14.
Valentini, F., et al. (2003). Carbon nanotube-based sensors for clinical and environmental monitoring. Analytical Chemistry, 75(20), 5413–5421.
Gooding, J. J. (2005). Nanostructuring electrodes with carbon nanotubes: A review on electrochemistry and applications. Electrochimica Acta, 50(15), 3049–3060. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
How can digital sensing technologies best support personalized cancer care?
|
2. By collecting real-time data on patient-specific symptoms and responses |
|
Digital sensing technologies such as wearable biosensors, smartphone-linked devices, and implantable monitors can continuously collect real time physiological and biochemical data unique to each patient. These data may include tumor biomarker levels, treatment responses, vital signs, side effects, and lifestyle behaviors.
By tracking how an individual patient responds to therapies, clinicians can personalize treatment plans—adjusting dosage, selecting targeted drugs, or even predicting side effects in advance. This leads to more effective, timely, and patient-centered cancer care, a cornerstone of precision medicine.
In contrast, population-level data or generalized approaches may overlook individual variability, while genetic-only focus misses environmental and lifestyle influences. |
Personalized medicine principle:
Treatment should be tailored to the individual’s biological, clinical, and behavioral profile. Digital sensing technologies enhance this by offering continuous, high-resolution, real-world data, unlike periodic hospital visits.
Key technologies:
Wearable electrochemical biosensors
Digital health platforms with AI integration
Real-time biomarker and symptom tracking
Key references:
Topol, E. (2019). Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Basic Books.
Esteva, A., et al. (2019). A guide to deep learning in healthcare. Nature Medicine, 25(1), 24–29.
Subramanian, I., et al. (2020). Multi-omics data integration, interpretation, and its application. Bioinformatics and Biology Insights, 14, 1177932219899051. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
If a clinician needs to monitor fatigue and motion in cancer patients at home, which device should be prioritized?
|
2. Smart accelerometers in wearables |
|
To monitor fatigue and motion in cancer patients at home, the most suitable and practical tool is a smart accelerometer embedded in wearable devices (e.g., smartwatches, fitness bands, or chest patches). These sensors continuously record movement patterns, physical activity levels, and even postural changes, which are critical indicators of fatigue, functional decline, or recovery progress in cancer patients.
Smart accelerometers can transmit data wirelessly in real time, allowing clinicians to remotely assess patients' mobility trends and energy levels, detect signs of fatigue or frailty, and intervene early when needed—without requiring the patient to visit the hospital. |
Accelerometry and patient monitoring:
Accelerometers measure linear acceleration across multiple axes (e.g., X, Y, Z), which helps infer steps, movement intensity, and inactivity periods—key proxies for fatigue and physical function.
Remote patient monitoring (RPM):
Wearable accelerometers are central to RPM systems, providing continuous, non-invasive, and low-burden data collection in real-world conditions.
Advantages:
Lightweight and comfortable for daily use
Real-time data transmission to clinicians
Integration with mobile apps for feedback and alerts
Key references:
Dunn, J., et al. (2018). Wearable sensors: Opportunities and challenges for cancer clinical trials. Nature Reviews Clinical Oncology, 15(12), 747–760.
Falck, R. S., et al. (2016). Accelerometer-based physical activity monitoring in cancer survivors: a systematic review. Clinical Oncology, 28(10), 667–680.
Patel, M. S., et al. (2020). Harnessing wearable device data to improve cancer care. JCO Clinical Cancer Informatics, 4, 1015–1024. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Why is combining sensor data with patient-reported outcomes (PROs) important in digital cancer care?
|
3. It allows a holistic understanding of patient experience |
|
Combining sensor data (such as movement, heart rate, sleep patterns, or biomarker levels) with patient-reported outcomes (PROs)—which include symptoms like pain, fatigue, emotional well-being, and treatment side effects enables clinicians and researchers to gain a comprehensive, patient-centered view of how cancer and its treatment affect a person's daily life.
While sensors provide objective, continuous, physiological data, PROs capture subjective experiences that cannot be measured electronically, such as nausea, anxiety, or social limitations. Together, they give a richer, contextual understanding of the patient's condition, which supports personalized treatment adjustments, early symptom management, and improved quality of life. |
Holistic cancer care:
Cancer affects both the body and mind. PROs bring in the patient voice, while sensor data offers continuous, quantitative physiological measurements. Integration helps tailor interventions based not just on biomarkers, but also on how the patient feels and functions.
Digital health model:
Multimodal data (sensor + PRO) is a cornerstone of precision oncology and value-based care, improving clinical decision-making, remote monitoring, and patient engagement.
Key references:
Basch, E., et al. (2017). Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. JAMA, 318(2), 197–198.
Chan, A., et al. (2019). Patient-reported outcomes: The missing link in digital health for cancer care. The Lancet Oncology, 20(5), e234–e243.
Petersen, C., et al. (2021). Combining wearable sensor data and patient-reported outcomes for cancer care: A narrative review. Digital Biomarkers, 5(2), 83–94. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
A hospital invested in wearable digital monitoring but received low engagement from patients. Which of the following is most likely a contributing factor?
|
3. Low digital health literacy among patients |
|
One major reason for low patient engagement with wearable digital monitoring is low digital health literacy. This means patients may lack the skills or confidence to effectively use digital devices, apps, or interpret health data. If patients struggle with navigating technology, they are less likely to consistently wear devices, input data, or respond to prompts, leading to underutilization of the monitoring system.
Even with good internet and well-designed dashboards, the human factor patients’ familiarity and comfort with technology remains critical for success. Addressing this requires patient education, user-friendly design, and support systems to improve digital literacy and motivation. |
Digital health literacy:
Defined as the ability to seek, understand, and use digital health information and tools to make informed decisions. Low literacy is linked to poorer health outcomes and less use of digital health interventions.
User engagement theory:
Engagement depends not only on technology quality but also on user capability, motivation, and opportunity (COM-B model).
Key references:
Norman, C. D., & Skinner, H. A. (2006). eHealth literacy: Essential skills for consumer health in a networked world. Journal of Medical Internet Research, 8(2), e9.
Stellefson, M., et al. (2017). Digital health literacy and patient engagement. Health Education & Behavior, 44(2), 284–290.
Neter, E., & Brainin, E. (2019). Association between health literacy and health behaviors. Journal of Health Communication, 24(7), 720–728. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
Which future trend is most aligned with the development of emerging digital cancer platforms?
|
2. Creation of pocket-sized biosensing tools integrated with smartphones |
|
Emerging digital cancer platforms focus on portable, accessible, and real-time diagnostics to improve early detection, monitoring, and personalized care. The development of pocket-sized biosensing tools integrated with smartphones aligns perfectly with this trend by enabling point of care testing anywhere and anytime.
Such devices use nanotechnology-based sensors, miniaturized electronics, and wireless connectivity to deliver rapid results, facilitating timely clinical decisions. This approach enhances patient convenience, reduces healthcare costs, and supports remote monitoring, which is vital for managing cancer effectively.
In contrast, trends like completely replacing pathology labs or abandoning AI are unrealistic given current technological advancements and healthcare needs. |
Mobile health (mHealth) and biosensing:
Integration of biosensors with smartphones is a key advancement in digital health, leveraging ubiquitous devices to democratize diagnostics.
Technological enablers:
Miniaturized electrochemical sensors
Wireless data transmission
User-friendly interfaces for patients and clinicians
Key references:
Kim, J., et al. (2019). Wearable biosensors for healthcare monitoring. Advanced Healthcare Materials, 8(1), 1800184.
Wang, J. (2015). Smartphone biosensors for health monitoring. ACS Sensors, 1(6), 738–742.
Zhang, Y., et al. (2021). Smartphone-based biosensors: Current advances and challenges. Biosensors and Bioelectronics, 171, 112739. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How can real-time symptom monitoring positively affect treatment decisions?
|
3. By enabling rapid intervention before major deterioration |
|
Real time symptom monitoring allows clinicians to continuously track patients’ health status, capturing early signs of worsening symptoms or adverse reactions to treatment. This immediate feedback enables healthcare providers to adjust treatment plans promptly, such as modifying drug dosage, managing side effects, or scheduling urgent consultations, before the patient’s condition significantly deteriorates.
Early interventions based on real-time data can improve treatment effectiveness, reduce hospitalizations, and enhance quality of life. Delaying changes or relying on intermittent assessments risks missing critical windows for optimal care. |
Remote patient monitoring theory:
Continuous data collection supports proactive healthcare, shifting from reactive to preventive management.
Clinical decision support:
Real time data integrated with clinical protocols and AI can alert clinicians to important trends, improving decision speed and accuracy.
Key references:
Basch, E., et al. (2017). Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. JAMA, 318(2), 197–198.
Mooney, K., et al. (2017). The impact of remote monitoring on cancer care: A systematic review. Supportive Care in Cancer, 25(6), 1935–1942.
Kvedar, J. C., et al. (2014). Connected health: a review of technologies and strategies to improve patient care with telemedicine and remote monitoring. Health Affairs, 33(2), 194–199. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
Which technology is best suited to detect rare cancer biomarkers with high precision?
|
1. Digital ELISA |
|
Digital ELISA (Enzyme Linked Immunosorbent Assay) is a highly sensitive and precise technology designed to detect ultra-low concentrations of biomarkers, including rare cancer biomarkers. Unlike conventional ELISA, digital ELISA partitions the sample into thousands of tiny compartments, allowing for single-molecule detection and significantly improving sensitivity and precision.
This technology is essential for early cancer diagnosis, where biomarker levels in blood or other fluids are often extremely low but critically important for timely treatment. |
Digital ELISA principle:
Based on digital counting of enzyme-linked antibody reactions in microcompartments, enabling single-molecule resolution and quantification.
Advantages over traditional methods:
Lower detection limits (femtomolar to attomolar)
High specificity due to antibody-based recognition
Reduced background noise
Key references:
Rissin, D. M., et al. (2010). Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nature Biotechnology, 28(6), 595–599.
Cohen, L., et al. (2017). Digital ELISA for early detection of cancer biomarkers. Clinical Chemistry, 63(3), 523–531.
Wilson, D. H., & Rissin, D. M. (2019). Ultra-sensitive digital ELISA: new frontiers in biomarker detection. Trends in Analytical Chemistry, 121, 115692. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
Why is collaboration between data scientists and clinicians essential in digital oncology platforms?
|
3. Data insights require clinical validation for real-world use |
|
In digital oncology platforms, data scientists develop algorithms and analyze complex datasets to generate predictive models and identify patterns. However, these data-driven insights must be clinically validated by clinicians to ensure they are medically relevant, accurate, and safe to apply in real-world patient care.
Clinicians provide the medical expertise, patient context, and ethical judgment needed to interpret the data appropriately and integrate it into treatment decisions. Without this collaboration, AI or analytics tools risk producing misleading or non-actionable results that could compromise patient outcomes. |
Interdisciplinary collaboration:
Effective healthcare analytics relies on combining technical expertise in data science with clinical knowledge and experience for meaningful interpretation.
Clinical validation:
Involves testing algorithms against clinical standards, patient populations, and outcomes to verify their utility and reliability.
Key references:
Topol, E. (2019). Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Basic Books.
Esteva, A., et al. (2019). A guide to deep learning in healthcare. Nature Medicine, 25(1), 24–29.
Rajkomar, A., et al. (2019). Machine learning in medicine. New England Journal of Medicine, 380(14), 1347–1358. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
Which outcome is most likely when cancer patients actively use digital health tools to track their condition?
|
2. They engage more actively in shared treatment decisions |
|
When cancer patients actively use digital health tools such as symptom trackers, wearable sensors, and patient portalsthey gain better insights into their own health status and treatment progress. This increased awareness empowers them to communicate more effectively with healthcare providers and participate in shared decision-making regarding their care plans.
Active engagement fosters collaboration between patients and clinicians, leading to improved adherence, personalized treatments, and better health outcomes. It contrasts with passive patient roles where decisions are clinician driven without patient input. |
Patient engagement theory:
Access to timely and relevant health information increases patient self-efficacy and motivation to participate in care decisions.
Shared decision-making:
A collaborative process in which clinicians and patients exchange information and agree on treatment goals and options.
Key references:
Shay, L. A., & Lafata, J. E. (2015). Shared decision making and patient outcomes. Medical Care Research and Review, 72(2), 129–149.
Barello, S., et al. (2016). Patient engagement in cancer care. Supportive Care in Cancer, 24(6), 2829–2837.
Graffigna, G., et al. (2017). Digital health and patient engagement. JMIR, 19(1), e17. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
A research team is developing a highly selective electrochemical sensor for detecting cancer biomarkers in blood. Based on the diagram, which combination of nanoparticle properties would most likely enhance both specificity and signal sensitivity?
|
2. Small spherical particles with antibody-conjugated targeting ligands |
|
Small spherical nanoparticles offer a high surface-to-volume ratio, enhancing surface interactions and increasing sensitivity by providing more active sites for binding.
Antibody conjugated targeting ligands on the nanoparticle surface provide high specificity by selectively binding to the unique cancer biomarkers.
This combination maximizes both signal sensitivity (due to high surface area and effective electron transfer) and specificity (due to antibody-antigen recognition), essential for accurate cancer biomarker detection in complex biological fluids like blood. |
Nanoparticle size and shape:
Smaller spherical nanoparticles maximize the accessible surface area and improve electrochemical properties (e.g., conductivity and catalytic activity).
Surface functionalization:
Conjugation of antibodies or aptamers ensures selective binding to target biomarkers, reducing non-specific adsorption and false signals.
Key references:
Daniel, M.-C., & Astruc, D. (2004). Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chemical Reviews, 104(1), 293–346.
Dreaden, E. C., et al. (2012). The golden age: gold nanoparticles for biomedicine. Chemical Society Reviews, 41(7), 2740–2779.
Wang, J. (2005). Carbon-nanotube based electrochemical biosensors: A review. Electroanalysis, 17(1), 7–14. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
A hospital is planning to adopt a single digital sensing platform to support a wide range of diagnostic applications. Based on the image, which of the following most justifies this decision?
|
2. One platform can be customized to detect toxins, cancer biomarkers, and heavy metals using interchangeable biorecognition elements |
|
Modern digital sensing platforms are often designed to be versatile and modular, allowing the same core device to be used for multiple diagnostic applications by simply changing the biorecognition elements (e.g., antibodies, aptamers, enzymes) on the sensor surface. This adaptability enables the platform to detect a broad range of targets such as toxins, cancer biomarkers, and heavy metals without needing separate machines for each analyte.
This approach reduces costs, streamlines workflow, and improves scalability, making it practical for hospitals to adopt a single system that supports diverse diagnostic needs. |
Modularity in biosensors:
Core transduction mechanisms (electrochemical, optical, etc.) can be reused while swapping specific bioreceptors tailored to different analytes.
Biorecognition elements:
They provide selectivity by binding specifically to target molecules; interchangeable ligands expand the platform’s application range.
Key references:
Justino, C. I. L., et al. (2017). Biosensors for environmental monitoring: a review. Talanta, 160, 264–277.
Wang, J. (2015). Electrochemical biosensors: towards point-of-care cancer diagnostics. Biosensors and Bioelectronics, 64, 20–29.
Cui, X., et al. (2021). Modular biosensing platforms for multiplexed detection. Trends in Analytical Chemistry, 143, 116383. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|